葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

盘后交易 07-21 19:07:35 EDT

50.78

+0.74

+1.48%

盘后50.70

-0.08-0.16%

18:44 EDT

最高51.31	最低50.16	成交量390.15万
今开50.26	昨收50.04	日振幅2.30%
总市值1,027亿	流通市值988.63亿	总股本20.23亿
成交额1.98亿	换手率0.20%	流通股本19.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":50.78,"timestamp":1784664000000,"preClose":50.04,"halted":0,"volume":3901504,"hourTrading":{"tag":"盘后","latestPrice":50.7,"preClose":50.78,"latestTime":"18:44 EDT","volume":21676,"amount":1100699.25988,"timestamp":1784673892691,"change":-0.08,"changeRate":-0.001575,"amplitude":0.001575},"delay":0,"changeRate":0.014788169464428498,"floatShares":1946891708,"shares":2022697682,"eps":3.736205,"marketStatus":"盘后交易","change":0.74,"latestTime":"07-21 19:07:35 EDT","open":50.26,"high":51.31,"low":50.16,"amount":197785629.44985598,"amplitude":0.022982,"askPrice":51.09,"askSize":75,"bidPrice":50.2,"bidSize":10,"shortable":3,"etf":0,"ttmEps":3.736205,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784678400000},"marketStatusCode":4,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":50.04,"dividendRate":0.03449,"preHourTrading":{"tag":"盘前","latestPrice":50.21,"preClose":50.04,"latestTime":"09:29 EDT","volume":80306,"amount":4041919.83288,"timestamp":1784640597159,"change":0.17,"changeRate":0.003397,"amplitude":0.030785},"postHourTrading":{"tag":"盘后","latestPrice":50.7,"preClose":50.78,"latestTime":"18:44 EDT","volume":21676,"amount":1100699.25988,"timestamp":1784673892691,"change":-0.08,"changeRate":-0.001575,"amplitude":0.001575},"volumeRatio":0.744575,"impliedVol":0.3489,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/GSK/wiki","defaultTab":"wiki","newsList":[{"id":"1161441653","title":"财报前瞻｜葛兰素史克本季度营收预计增3.77%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1161441653","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161441653?lang=zh_cn&edition=full","pubTime":"2026-07-21 08:16","pubTimestamp":1784592973,"startTime":"0","endTime":"0","summary":"葛兰素史克将于2026年07月28日美股盘前发布最新季度财报，市场聚焦营收、盈利质量与管线变动对短中期业绩的影响。市场一致预期本季度营收约109.81亿美元，同比增长3.77%；调整后每股收益约1.24美元，同比增长10.63%；息税前利润约34.88亿美元，同比增长7.64%。上季度公司实现营收102.82亿美元，同比增长8.60%；毛利率75.45%；归母净利润17.37亿美元，净利率22.77%；调整后每股收益1.25美元，同比增长10.79%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜葛兰素史克本季度营收预计增3.77%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104964436","title":"异动解读｜葛兰素史克盘中下跌3.02%，止咳新药三期临床失利致20亿美元并购核心管线终止开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1104964436","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104964436?lang=zh_cn&edition=full","pubTime":"2026-07-21 03:37","pubTimestamp":1784576228,"startTime":"0","endTime":"0","summary":"7月17日，葛兰素史克盘中下跌3.02%，报50.19美元/股，成交额2.16亿美元。消息面上，公司宣布终止camlipixant在难治性慢性咳嗽适应症的开发。该药物为高选择性P2X3受体拮抗剂，系GSK斥资20亿美元全额现金收购Bellus Health的核心资产。三期临床数据显示，50mg剂量在CALM-1试验中显著降低24小时咳嗽频率，但在CALM-2试验中未达统计学显著性，25mg剂量在两项试验中均未达主要终点。本次核心呼吸管线失败大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136771666","title":"异动解读｜葛兰素史克盘中下跌3.02%，止咳新药三期临床失利致20亿美元并购核心管线终止开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1136771666","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136771666?lang=zh_cn&edition=full","pubTime":"2026-07-18 01:47","pubTimestamp":1784310431,"startTime":"0","endTime":"0","summary":"7月17日，葛兰素史克盘中下跌3.02%，报51.175美元/股，成交额4.04亿美元。消息面上，公司宣布终止camlipixant在难治性慢性咳嗽适应症的开发。该药物为高选择性P2X3受体拮抗剂，系GSK于2023年斥资20亿美元全额现金收购Bellus Health的核心资产，原本被市场寄予填补难治性慢性咳嗽临床空白的厚望。本次核心呼吸管线失败大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652784289","title":"葛兰素史克(GSK)跌2.3% 止咳新药三期临床失利 20亿并购核心管线宣告终止开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652784289","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652784289?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:32","pubTimestamp":1784298747,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药企葛兰素史克 股价承压，报51.56美元，跌2.29%。该药物为高选择性 P2X3 受体拮抗剂，是 2023 年 GSK 斥 20 亿美元全额现金收购 Bellus Health 的核心资产，原本被市场寄予厚望，用于填补难治性慢性咳嗽临床空白。本次 20 亿并购的核心呼吸管线宣告失败，大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期；肠易激综合征赛道市场空间相对有限，难以完全对冲止咳适应症临床失利带来的估值压力。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302703","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","BK4532","XMMO","GSK","BK4588","GSK.UK","CALF","GSKH","KCE","MYLD","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126067447","title":"异动解读｜葛兰素史克盘前下跌4.42%，报50.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126067447","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126067447?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:34","pubTimestamp":1784277248,"startTime":"0","endTime":"0","summary":"7月17日，葛兰素史克盘前下跌4.42%，报50.41美元/股，成交额95.17万美元。葛兰素史克所在的制药行业中，个股中，礼来涨0.58%，强生涨0.87%，默沙东涨0.48%，辉瑞涨0.06%，Atai Beckley Inc跌0.97%。GSK Plc是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成，致力于开发较现有治疗方案明显改善的新产品。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910625","title":"中国生物制药早盘涨超5% 与GSK进一步深化独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910625","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650910625?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:12","pubTimestamp":1783563120,"startTime":"0","endTime":"0","summary":"　　中国生物制药早盘涨超5%，截至发稿，股价上涨5.39%，现报5.08港元，成交额2.39亿港元。　　7月8日，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克“GSK”于2026年5月达成的独家战略合作，推动两款呼吸领域重磅创新药物惠及更多中国患者。本次合作是集团与GSK战略合作的又一重要进展，标志着双方合作领域从肝病进一步拓展至呼吸系统疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-09/doc-inihench4479325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1521","IE00BZ08YT58.USD","BK1589","BK4007","BK4588","GSK","BK4532","01177","GSK.UK","LU1829250122.USD","BK1191","BK1515","IE00BZ08YR35.GBP","GSKH","IE00BZ08YS42.EUR","HK0000165453.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096193","title":"GSK将两款呼吸疾病药物中国商业化权益授予正大天晴，MNC在华战略调整加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096193","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649096193?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:50","pubTimestamp":1783500612,"startTime":"0","endTime":"0","summary":"而此前，就在今年5月，正大天晴获得GSK乙肝新药Bepirovirsen在中国内地的独家商业化权利。事实上，不只GSK，跨国药企在华战略近年来正在加速调整。一方面，MNC将成熟管线的商业化权益交给国内企业，另一方面，MNC正在加大力度购买中国药企的创新管线。从商业化到研发，内、外资药企的战略调整还在加速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783500577933587278","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GSK.UK","GSK","GSKH","BK4588","LU1829250122.USD","BK4585","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969580","title":"中国生物制药分别与阿斯利康、葛兰素史克达成重要合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969580","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649969580?lang=zh_cn&edition=full","pubTime":"2026-07-08 15:55","pubTimestamp":1783497300,"startTime":"0","endTime":"0","summary":"7月8日，中国生物制药有限公司（以下简称“中国生物制药”）公告称，将自主研发的慢性阻塞性肺疾病（COPD）创新药TQC3721（PDE3/4抑制剂）海外权益以总额最高19亿美元授权给阿斯利康，创下近三年中国呼吸领域单产品交易额之最；同日，中国生物制药还宣布将进一步深化与葛兰素史克（GSK）的战略合作，获得GSK两款全球重磅呼吸创新药在中国内地的独家商业化权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798367659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B3T34201.USD","IE00BZ08YR35.GBP","01177","LU2089984988.USD","LU0310800379.SGD","IE00BZ08YT58.USD","GSK.UK","HK0000165453.HKD","LU0029864427.USD","LU0889565916.HKD","LU2237443382.USD","LU0128525929.USD","LU2468319806.SGD","BK1515","BK1191","LU2237443465.HKD","LU2236285917.USD","LU2417539215.USD","LU0320765992.SGD","LU2237443978.SGD","GSKH","GSK","LU2237443895.HKD","BK1521","LU0109394709.USD","IE00BZ08YS42.EUR","LU0289739699.SGD","LU0058720904.USD","BK4585","AZN","BK4588","LU2456880835.USD","LU1829250122.USD","BK4532","LU2237443549.SGD","BK4568","AZNH","LU1267930573.SGD","LU0432979614.USD","BK1589","LU2237443622.USD","BK4007","LU0708994859.HKD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649027952","title":"葛兰素史克与中国生物制药深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649027952","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649027952?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:14","pubTimestamp":1783484047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","01177","GSKH","LU1829250122.USD","IE00BZ08YT58.USD","BK1589","GSK","BK1521","BK1515","BK4532","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1191","BK4007","HK0000165453.HKD","BK4585","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649072952","title":"中国生物制药：深化与GSK呼吸领域战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649072952","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649072952?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483560,"startTime":"0","endTime":"0","summary":"【中国生物制药：深化与GSK呼吸领域战略合作】南财智讯7月8日电，中国生物制药（01177.HK）发布自愿公告，宣布其附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克（GSK）于2026年5月达成的独家战略合作，获得GSK两款呼吸领域创新药——氟替美维吸入粉雾剂（商品名：全再乐）和乌美溴铵维兰特罗吸入粉雾剂（商品名：欧乐欣）在中国内地的商业化权益，包括进口、分销、医院准入及推广活动，相关销售收入全额确认为正大天晴营业收入。本次合作系双方继肝病领域后首次拓展至呼吸系统疾病，标志本集团呼吸管线从研发向商业化全面升级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","BK4588","BK4585","HK0000165453.HKD","IE00BZ08YS42.EUR","01177","GSKH","IE00BZ08YT58.USD","BK1191","GSK","LU1829250122.USD","BK4007","GSK.UK","BK1515","IE00BZ08YR35.GBP","BK4532","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648703689","title":"美股异动 | 医药板块再获资金切换 葛兰素史克(GSK.US)涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648703689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648703689?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:41","pubTimestamp":1783006872,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，医药板块再获资金切换，葛兰素史克(GSK.US)涨近5%，诺和诺德(NVO.US)、赛诺菲安万特(SNY.US)涨超3%，礼来(LLY.US)涨超2%。分析指出，近期科技股、AI大模型及半导体板块持续调整，以及市场对AI算力投资过热、成本控制及高估值产生严重担忧，相关板块出现高位震荡与获利回吐，资金集中向具有强刚需、受经济周期冲击小的医药板块切换。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","BK4585","GSKH","GSK","BK1161","159938","BK4007","LU1829250122.USD","BK1515","09939","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141965771","title":"异动解读｜葛兰素史克盘中上涨3.02%，制药板块整体走强叠加收购Nuvalent推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1141965771","media":"行情直击","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141965771?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:00","pubTimestamp":1783000832,"startTime":"0","endTime":"0","summary":"7月2日，葛兰素史克盘中上涨3.02%，报53.00美元/股，成交额1425.27万美元。消息面上，制药板块当日整体表现强势，阿斯利康涨3.9%、诺和诺德涨3.42%，行业情绪明显回暖。与此同时，葛兰素史克旗下子公司此前已正式发起对Nuvalent的要约收购，以每股124美元全现金方式收购其全部流通股，要约截止日期为7月14日。该笔106亿美元的交易是公司十年来最大规模并购，旨在补强肺癌药物管线，Nuvalent董事会已建议股东接受要约。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645281618","title":"葛兰素史克宣布要约收购Nuvalent。","url":"https://stock-news.laohu8.com/highlight/detail?id=2645281618","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645281618?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:54","pubTimestamp":1782309271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","BK4139","BK4007","GSKH","BK4585","BK4532","BK4539","GSK.UK","BK4588","GSK","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756361","title":"摩根大通：生物药企融资回暖 大型药企行业并购优先级高于独立IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756361","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643756361?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:21","pubTimestamp":1781605294,"startTime":"0","endTime":"0","summary":"多数本土生物科技企业采取双轨策略，同步筹备 IPO、对接药企收购资源，不少企业上市落地前完成并购交割。头部药企偏好数十亿美金中型补充式并购，近期葛兰素史克斥资 106 亿美元收购肿瘤药企 Nuvalent，打破中小型并购定价惯例。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301588","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640476718.USD","LU1496350502.SGD","IE0034235303.USD","JPX","LU0265550946.USD","LU1894683348.USD","BK4504","BK4566","LU0070302665.USD","LU0942090050.USD","LU0964807845.USD","JPM","IE00BKDWB100.SGD","LU2237443622.USD","PGF","SG9999002224.SGD","LU1366192091.USD","LU0820562030.AUD","LU2592432038.USD","IE00BJJMRZ35.SGD","159839","LU0251132253.USD","LU1064131342.USD","BK4578","LU2357305700.SGD","JPMO","LU0238689110.USD","JPO","LU0310799852.SGD","LU1548497426.USD","LU0211331839.USD","LU0976567544.SGD","IE00B1XK9C88.USD","LU0689472784.USD","IE00B2B36J28.USD","IE0009355771.USD","LU1261432733.SGD","NVS","LU2211815571.USD","LU0345769128.USD","IE00BYXW3230.USD","GSK","LU0215105999.USD","LU2357627491.SGD","GSKH","LU1629891620.HKD","LU2505996509.AUD","GSK.UK","IE00B3S45H60.SGD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286033","title":"GSK十年来最大一笔并购，对中国Biotech的四点启示","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286033","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642286033?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:59","pubTimestamp":1781175583,"startTime":"0","endTime":"0","summary":"这事儿，挺值得咱们中国的Biotech琢磨琢磨的。过去十年，中国创新药习惯了自己的坐标系。中国Biotech肯定不缺科学，但这种跳出自身坐标系、站在买家视角重新丈量自己价值的自觉，或多或少差了些。这对咱们中国Biotech第二个启示，就是别再净那些“万金油”式的东西了。而GSK这次可不一样。这，或许就是那张价值106亿美元倒计时牌，给咱们的Biotech上的最好一课。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1781143796640652546","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GSKH","BK4581","BK4007","BK4532","BK4585","GSK","XBI","GSK.UK","LU1829250122.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642189402","title":"重返肿瘤核心战场 葛兰素史克(GSK.US)能否借Nuvalent缩小与阿斯利康差距？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642189402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642189402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:56","pubTimestamp":1781164594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克以创纪录的106亿美元收购美国生物技术公司Nuvalent，此举将加快这家英国制药巨头旗下抗癌药物业务的重建步伐，以应对来自更大竞争对手阿斯利康和罗氏的竞争压力。米尔斯在周二宣布收购Nuvalent后对记者表示。葛兰素史克并不打算在全部肿瘤领域与默沙东、阿斯利康或罗氏正面竞争，但将其视为潜在的增长领域。收购Nuvalent将为葛兰素史克产品组合增添两款晚期药物。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2237443622.USD","LU0058720904.USD","BK4532","LU0320765992.SGD","AZN","LU2237443978.SGD","LU2237443895.HKD","GSK.UK","BK4568","IE00B3T34201.USD","LU2417539215.USD","GSK","BK4007","LU2236285917.USD","AZNH","BK4539","BK4588","NUVL","GSKH","LU1829250122.USD","LU2462157665.USD","LU2456880835.USD","LU2237443549.SGD","LU0109394709.USD","LU2237443465.HKD","LU0889565916.HKD","LU2237443382.USD","LU0289739699.SGD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642671094","title":"Nuvalent股价飙升 此前GSK宣布收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2642671094","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642671094?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:10","pubTimestamp":1781007000,"startTime":"0","endTime":"0","summary":"英国生物制药公司葛兰素史克宣布以106亿美元收购美国药企Nuvalent，后者股价随即飙升近39%。\n　　这项全现金交易对Nuvalent的估值约为每股124美元。Nuvalent目前有两款治疗某种肺癌的药物正在接受美国食品药品监督管理局的审评。\n　　葛兰素史克首席执行官卢克·米尔斯在新闻稿中表示，此次收购将为公司带来即时的新的销售增长机遇。这家药企在美国上市的股票周二盘前交易中下跌1%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniavmyr1715814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4139","GSK.UK","BK4532","BK4585","LU1829250122.USD","NUVL","GSK","GSKH","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642668054","title":"英国葛兰素史克斥资106亿美元收购美国药企Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2642668054","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642668054?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:28","pubTimestamp":1780997280,"startTime":"0","endTime":"0","summary":"英国制药集团葛兰素史克达成协议，以 106 亿美元收购美国药企 Nuvalent。本次收购正值全球生物医药并购热潮期。　　英国制药巨头葛兰素史克敲定收购美国药企 Nuvalent 的交易，交易总价 106 亿美元，核心目的是补强自身肺癌药物管线。　　葛兰素史克周二披露公告显示，本次交易为全现金收购，对 Nuvalent 的估值折合每股 124 美元，较该股前一交易日收盘价溢价 40%。　　英国《金融时报》周二早间率先曝出该并购消息，Nuvalent 方面暂未回应媒体置评请求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniauzkq6465243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4539","GSK","BK4588","GSKH","GSK.UK","LU1829250122.USD","NUVL","BK4585","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642450645","title":"溢价40%！葛兰素史克拟以106亿美元收购Nuvalent，加码癌症药物领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2642450645","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642450645?lang=zh_cn&edition=full","pubTime":"2026-06-09 15:37","pubTimestamp":1780990654,"startTime":"0","endTime":"0","summary":"6月9日，$葛兰素史克$同意以106亿美元的价格收购肿瘤治疗药企Nuvalent。$葛兰素史克$周二发布声明称，将以每股124美元现金收购Nuvalent，较这家总部位于马萨诸塞州$剑桥$的公司周一收盘价溢价40%。此次收购标志着葛兰素史克癌症业务的重大扩张。Nuvalent的两款主要药物用于治疗携带特定基因突变的非小细胞肺癌患者。葛兰素史克表示，在获得监管部门批准后，对Nuvalent的收购预计将于第三季度完成。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451912.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"溢价40%！葛兰素史克拟以106亿美元收购Nuvalent，加码癌症药物领域","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","LU1829250122.USD","BK4139","BK4585","GSK","BK4007","NUVL","BK4532","BK4588","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642567024","title":"最高溢价近43%!葛兰素史克(GSK.US)拟斥资90-100亿美元收购肿瘤药企Nuvalent(NUVL.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642567024","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642567024?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:18","pubTimestamp":1780975127,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克正就收购肿瘤治疗药企Nuvalent Inc.进行磋商，交易对价在90亿至100亿美元之间。本次交易将对总部位于马萨诸塞州剑桥市的Nuvalent给出高额溢价，这也将成为葛兰素史克史上规模最大的收购案之一。在退出肿瘤领域多年后，葛兰素史克近期才重新回归这一赛道。今年1月，葛兰素史克曾同意以22亿美元收购一家专注于炎症与免疫疾病治疗药物研发的美国生物科技公司Rapt Therapeutics，并在另一笔交易中获得了一款肺动脉高压药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSKH","LU1829250122.USD","GSK","BK4532","GSK.UK","BK4007","BK4539","NUVL","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.043},{"period":"1month","weight":-0.0124},{"period":"3month","weight":-0.1083},{"period":"6month","weight":0.041},{"period":"1year","weight":0.3781},{"period":"ytd","weight":0.0204}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.010234},{"month":7,"riseRate":0.531915,"avgChangeRate":0.002895},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}